About gyre therapeutics inc - GYRE
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
GYRE At a Glance
Gyre Therapeutics, Inc.
12770 High Bluff Drive
San Diego, California 92130
| Phone | 1-619-949-3681 | Revenue | 116.59M | |
| Industry | Pharmaceuticals: Major | Net Income | 5.03M | |
| Sector | Health Technology | 2025 Sales Growth | 10.241% | |
| Fiscal Year-end | 12 / 2026 | Employees | 625 | |
| View SEC Filings |
GYRE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 313.778 |
| Price to Sales Ratio | 6.248 |
| Price to Book Ratio | 6.08 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 50.904 |
| Enterprise Value to Sales | 6.117 |
| Total Debt to Enterprise Value | 0.001 |
GYRE Efficiency
| Revenue/Employee | 186,540.80 |
| Income Per Employee | 8,043.20 |
| Receivables Turnover | 3.156 |
| Total Asset Turnover | 0.80 |
GYRE Liquidity
| Current Ratio | 5.598 |
| Quick Ratio | 5.042 |
| Cash Ratio | 2.867 |
GYRE Profitability
| Gross Margin | 95.355 |
| Operating Margin | 9.856 |
| Pretax Margin | 12.382 |
| Net Margin | 4.312 |
| Return on Assets | 3.449 |
| Return on Equity | 5.937 |
| Return on Total Capital | 4.699 |
| Return on Invested Capital | 5.895 |
GYRE Capital Structure
| Total Debt to Total Equity | 0.886 |
| Total Debt to Total Capital | 0.878 |
| Total Debt to Total Assets | 0.565 |
| Long-Term Debt to Equity | 0.286 |
| Long-Term Debt to Total Capital | 0.283 |